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BACKGROUND Paclitaxel drug-eluting balloons (pDEB) are indicated
for PCI of in-stent restenosis (ISR), and may have a role in revascu-
larization of de-novo lesions (DNL). While the short-term efﬁcacy and
safety of pDEB has been reported from registries and a few random-
ized controlled trials, late follow-up is lacking. Thus we studied the
late efﬁcacy and safety of SequentPlease pDEB (B. Braun, Germany) in
PCI of DNL and ISR.
METHODS All 147 patients (188 lesions) undergoing PCI using pDEB at
Liverpool Hospital, Sydney from Oct 2011 to Mar 2015 were included. Ac-
cording to the PCI lesion-type, patientswere categorized into 2 groups: DNL
and ISR [prior bare-metal stent (BMS) or drug-eluting stent (DES)]. Baseline,
procedural, and clinical outcomedatawereobtained fromthedepartmental
database and treating physicians. The primary outcome was MACE: com-
posite of cardiac death, clinically driven pDEB target-lesion revasculariza-
tion (pDEB-TLR), and myocardial infarction (MI).
RESULTS Mean patient age was 6711 years (79% male), 39% pre-
sented with an acute coronary syndrome (ACS). Clinical follow up was
1.31.0 years. Lesions treated for ISR (n¼118) were more likely than
DNL (n¼70) to be in patients with diabetes mellitus (DM, 64 vs 37%;
p<0.001), impaired renal function (43 vs 20%; p<0.001), and multi-
vessel PCI (66 vs 46%; p¼0.006). Among patients with prior coronary
bypass grafting (CABG), DES ISR was more common than BMS ISR
(39% and 18%; p¼0.02). ACS patients were more likely treated for DNL
than ISR (50 vs 33%; p¼0.02). There was no difference between DNL
and ISR groups in target lesion complexity (61% type B2/C), target
lesion length (2112mm), and pDEB length (205mm). Smaller caliber
pDEBs were used for DNL compared to ISR (2.40.4 vs 2.80.6mm;
p<0.0001). For DNL compared to ISR: cardiac death was 3% vs 0%
(p¼0.06), DEB-TLR was 1% vs 12% irrespective of stent type (p¼0.02);
and respective dissection (grade D-F) rates were 7% and 5% (p¼0.56).
MACE event rates (Table 1) were similar for DNL and ISR (14 vs 25%,
p¼0.105), and for DES and BMS ISR subgroups (23 vs 27%, p¼0.55).
Cox multivariate analysis showed diabetes and prior CABG are
independent predictors of MACE in patients with ISR (HR 4.48, 1.34-
15, P¼0.015 and HR 3.22, 1.51-6.89, p¼0.003, respectively).
Table 1. Long-Term Clinical Outcomes for pDEBOutcomesDe novo
(n[70)ISR
(n[118) p-valueBMS-ISR
(n[39)DES-ISR
(n[79) p-valueCardiac
death
(%)2 (3) 0 0.06 0 0MI (%) 5 (7) 20 (17) 0.12 6 (15) 14 (18) 0.64pDEB-TLR
(%)1 (1) 15 (12) 0.02 3 (8) 12 (15) 0.22MACE (%) 8 (14) 30 (25) 0.15 9 (23) 21 (27) 0.55CONCLUSIONS In our real-world all-comer registry, pDEB appears to be a
safe and effective stent-sparing strategy for DNL in smaller caliber arteries.
pDEB use in DNL was associated with low rates of re-intervention, and had
similar MACE rates to ISR groups. DM and prior CABG predict poorer out-
comes for pDEB used in (BMS and DES) ISR.
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BACKGROUND Scoring balloons produce excellent acute results in
the treatment of in-stent restenosis, ﬁbro-calciﬁc and bifurcation le-
sions but have not been shown to affect the restenosis rate. A novel
paclitaxel-coated scoring balloon (SB) was developed and tested to
overcome this limitation.
METHODS SB were coated with paclitaxel admixed with a speciﬁc
excipient. Patients at four clinical sites in Germany and one in Brazil
with in-stent restenosis (ISR) of coronary bare metal stent (BMS) were
randomized 1:1 to treatment with either a drug-coated or uncoated SB.
Baseline and 6-month follow-up quantitative coronary angiography
was performed by an independent blinded core lab and all patients
will be evaluated clinically for up to one year. The primary endpoint
was angiographic in-segment late lumen loss (LLL). Secondary end-
points included the rate of clinically driven target lesion revasculari-
zation (TLR), composite of major adverse cardiovascular events
(MACE), stent thrombosis and other variables at two years follow-up.
RESULTS Sixty-one patients were randomized (28 uncoated and 33
drug-coated SB); mean age 65 years, males 72 %, and presence of
diabetes 39 %. At 6-month angiography, in-segment LLL was 0.48 
0.51 mm in the uncoated SB group versus 0.17  0.40 mm in the drug-
coated SB group (p¼0.01; ITT analysis). The rate of binary restenosis
was 41 % in the uncoated SB group versus 7 % in the drug-coated SB
group (p<0.01). The MACE rate at 2 years was 32 % with the uncoated
SB vs. 9 % in the drug-coated SB group (p<0.05). This difference was
primarily due to the reduced need for clinically driven TLR in the
coated SB group (3 % vs. 32 % p<0.01).
CONCLUSIONS A novel paclitaxel-coated coronary SB has been
developed and successfully used in a ﬁrst-in-human randomized
controlled trial [ClinicalTrials.gov Identiﬁer: NCT01495533].
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BACKGROUND The aim of this study was to evaluate the impact of neo-
intimal tissuecharacteristicsassessedbyOCTusinggray-scale intensity (GSI)
on treatment for in-stent restenosis (ISR) with drug-coated balloon (DCB).
METHODS Neointimal tissue characterization using OCT-based GSI
analysis was performed for a total of 25 patients with 32 ISR lesions
undergoing DCB treatment for ISR. Neointima were classiﬁed into
mature and non-mature tissue according to our previous data with
animal models and autopsy specimens.
RESULTS Of 637 regions of interest (ROI) assessed for neointimal
maturity, 248 ROIs (39%) were mature neointimal tissue. The higher
percentage of mature tissue was associated with smaller acute gain
after PCI with DCB (Figure). Clinical events and OCT ﬁndings at 6-8
month after DCB treatment for ISR lesions will be available at
presentation. Conclusions: OCT GSI analysis for neointima might
predict reactions after treatment with DCB for ISR lesions.
CONCLUSIONS OCT GSI analysis for neointima might predict re-
actions after treatment with DCB for ISR lesions.
